XENE - Xenon Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
311
1,803
15,577
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
15,577
Operating Expenses
Research Development
29,992
23,634
25,573
19,828
15,152
Selling General and Administrative
8,894
8,382
7,313
6,792
9,786
Total Operating Expenses
44,886
38,016
32,886
26,620
24,938
Operating Income or Loss
-44,886
-38,016
-32,575
-24,817
-9,361
Interest Expense
1,758
1,394
-
-
-
Total Other Income/Expenses Net
-12
3,697
1,394
1,316
-6,391
Income Before Tax
-44,285
-34,497
-30,704
-22,997
-15,752
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-44,289
-34,497
-30,704
-22,997
-15,752
Net Income
-44,289
-34,497
-30,704
-22,997
-15,752
Net Income available to common shareholders
-41,594
-31,616
-30,704
-22,997
-15,752
Reported EPS
Basic
-
-1.63
-1.71
-1.48
-1.10
Diluted
-
-1.63
-1.72
-1.48
-1.10
Weighted average shares outstanding
Basic
-
19,426
17,985
15,493
14,282
Diluted
-
19,426
18,002
15,493
14,282
EBITDA
-
-32,517
-31,926
-23,953
-9,361